Alex Keun Mo Yang, Chief Executive Officer, 10% Owner at Polaryx Therapeutics, Inc. (PLYX), bought 88,453 shares at $4.07 ($360K) on 2026-05-27, disclosed to the SEC on 2026-05-28.
CEO Alex Keun Mo Yang purchased $360,003.71 worth of shares at $4.07, marking the largest purchase of his career. This significant insider buying suggests confidence in the company's pipeline, specifically the upcoming presentation of Soteria trial data.
Insufficient data — needs manual review
Upcoming presentation of late-breaking data for PLX-200 at the 22nd Annual WORLDSymposium on February 2-6, 2026; CEO Alex Keun Mo Yang executed the largest purchase of his career, signaling confidence in the Soteria trial pipeline.
The company is a micro-cap biotech with a short float of only 0.94%, indicating limited short interest; however, the company is in the clinical trial phase, which carries inherent risks regarding trial outcomes and regulatory approval.
Something here stands out, but not much.